Beam Therapeutics Inc 10-Q for FY2026 Q3
Beam Therapeutics Inc. (BEAM)
10-Q
2026-11-03
For: 2026-09-30
View Original
Added on
November 03, 2026
About this 10-Q
Beam Therapeutics Inc filed this 10-Q on November 3, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).
Beam Therapeutics plans to submit a biologics license application (BLA) for risto-cel as early as year-end 2026, after completing dosing for all adult and adolescent patients in its BEACON trial. AI summary
Headline figures
Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.
- Revenue
- $307K
- down 96.8% from $9.7M a year earlier
- Net loss
- $134.41M
- compared with a net loss of $112.57M a year earlier
- Diluted EPS
- -$1.28
- compared with -$1.10 a year earlier